Circulating Benign Nevus Cells Detected by ISET Technique

Giorgi, Vincenzo De; Pinzani, Pamela; Salvianti, Francesca; Grazzini, Marta; Orlando, Claudio; Lotti, Torello; Pazzagli, Mario; Massi, Daniela

doi:10.1001/archdermatol.2010.264

Cited by 54 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been considerable interest in isolating and quantifying CTCs to develop new prognostic and predictive assays, but the mere presence of CTCs, isolated by virtue of expression of epithelial cell-surface markers, in the blood of patients does not always correlate with poorer prognosis or metastasis [43,44]. Although our work would suggest that normal epithelial cells are quite susceptible to FSS, cells with varying degrees of metastatic potential may nonetheless co-exist within the population of CTCs and circulating benign cells have been reported [45]. Moreover, we show that FSS resistance is increased by several oncogenes including ras, myc and PI3K.…”

Section: Discussionmentioning

confidence: 70%

Novel Biophysical Marker of Aggressive Prostate Cancer Cells

Henry¹

2013

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 5f. WORK UNIT NUMBER REPORT DATE PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)University of Iowa College of Medicine PERFORMING ORGANIZATION REPORT NUMBERIowa City, Iowa 52242 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTThe most significant finding of this research study during this period is the validation of resistance to fluid shear stress as a biomarker of prostate cancer cells. This initial finding has been published. Additional efforts have been undertaken to detect this biomarker in circulating tumor cells from blood samples from prostate cancer patients. This involves the development of methods to achieve this goal. Figure 2. We have applied this approach to an initial set of 3 prostate cancer patients in which a blood sample was taken 1d prior to prostatectomy and 1d post-operative. These initial findings are summarized in Figure 3. These findings are encouraging and suggest that CTCs are detectable by this method at the time of prostatectomy. In principle, our assay for FSS resistance could be applied at this time and this biomarker may indicate the degree to which these cells have the propensity to progress to metastasis. Additional findings are that very few cells detected are double-positive for EpCAM and N-Cadherin, and there is a possibility that CTC numbers increase from pre-operative to post-operative day 1, suggesting that surgical manipulation may increase CTC numbers in this setting. However, these findings are highly preliminary at this point. Additional studies are underway to confirm the identity of these cells as prostate CTC's by staining for PSA and/or PSMA. SUBJECT TERMSSOW 1c. Accrue and analyze patient samples (Months 9-23) As noted above, 3 patients have been accrued in the validation portion of this proposal. Once we have established that the cells we are measuring ate bona-fide prostate cancer CTCs, we will ...

show abstract

Section: Discussionmentioning

confidence: 70%

Novel Biophysical Marker of Aggressive Prostate Cancer Cells

Henry¹

2013

View full text Add to dashboard Cite

show abstract

“…De Giorgi and colleagues detected CTCs in 29% and 62.5% of patients with primary invasive and metastatic melanoma respectively, using qPCR to detect Tyrosinase transcripts after ISET ® filtration; the limit of detection was 1 CTC/ mL of blood [14]. However, this approach also detected benign circulating nevus cells [15], suggesting the inability of this assay to distinguish between benign nevus cells and melanoma cells. Alternatively, when using the same ISET enrichment technique, with CTCs defined by positive immunohistochemistry expression of S100 and negative expression for CD45 or CD144 (leukocyte and endothelial cell markers, respectively), 51/90 (57%) metastatic melanoma patients had detectable CTCs (1e44 CTCs/mL of blood) [29].…”

Section: Melanoma Ctc Enrichment Techniquesmentioning

confidence: 99%

Melanoma circulating tumor cells: Benefits and challenges required for clinical application

et al. 2018

View full text Add to dashboard Cite

a b s t r a c tThe implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.

show abstract

“…1) [49]. Sensitivity for melanoma, as opposed to circulating melanocytes, standardization of the choice of mRNA biomarkers, and agreement on clinically relevant thresholds remain consistent challenges for this approach [50,51].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

“…Unlike ctDNA isolation, RNA analysis has not provided clues as to differential protein amplification or expression profiles present among individuals with melanoma. A concerning study using tyrosinase mRNA as a biomarker found positive signal in a patient with a benign congenital nevus, bringing into question the specificity of tyrosinase and other melanocytic markers that serve as surrogates for CTCs [51]. Because of the long-term instability of RNA and cDNA when stored in freezers, the potential for using extracted products for downstream analysis and future applications is limited to approximately 1 year [49].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma

Dorsey

Amaravadi

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and messenger RNA (mRNA), collectively termed circulating tumor products (CTPs), represent areas of immense interest from scientists' and clinicians' perspectives. In melanoma, CTP analysis may have clinical utility in many areas, from screening and diagnosis to clinical decisionmaking aids, as surveillance biomarkers or sources of realtime genetic or molecular characterization. In addition, CTP analysis can be useful in the discovery of new biomarkers, patterns of treatment resistance, and mechanisms of metastasis development. Here, we compare and contrast CTCs, ctDNA, and mRNA, review the extent of translational evidence to date, and discuss how future studies involving both scientists and clinicians can help to further develop this tool for the benefit of melanoma patients. The Oncologist 2016;21:84-94 Implications for Practice: Scientific advancement has enabled the rapid development of tools to analyze circulating tumor cells, tumor DNA, and messenger RNA, collectively termed circulating tumor products (CTPs). A variety of techniques have emerged to detect and characterize melanoma CTPs; however, only a fraction has been applied to human subjects.This review summarizes the available human data that investigate clinical utility of CTP in cancer screening, melanoma diagnosis, prognosis, prediction, and genetic or molecular characterization. It provides a rationale for how CTPs may be useful for future research and discusses how clinicians can be involved in developing this exciting new technology.

show abstract

Circulating Benign Nevus Cells Detected by ISET Technique

Cited by 54 publications

References 12 publications

Novel Biophysical Marker of Aggressive Prostate Cancer Cells

Novel Biophysical Marker of Aggressive Prostate Cancer Cells

Melanoma circulating tumor cells: Benefits and challenges required for clinical application

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma

Contact Info

Product

Resources

About